Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Richard Macdonell et al.|JAMA Neurology|2023Cited by 62
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Helmut Butzkueven, Koen de Gans et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 17
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Nils Koch‐Henriksen et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Jonathan Ciron et al.|CNS Drugs|2021Cited by 12
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Tobias Sejbæk, Koen de Gans et al.|Frontiers in Neurology|2023Cited by 9